Postmenopausal Hormone Rx Reduces Glaucoma Risk

Monday, January 26, 2015

Postmenopausal Hormone Rx Reduces Glaucoma Risk

It has been reported that women entering menopause early-under age 45-are at increased risk of primary open angle glaucoma (POAG). It has been suggested that this is due to some protective effect of female hormones. Now, according to researchers publishing in JAMA Ophthalmology  taking estrogen only postmenopausal hormone (PMH) treatment may actually help reduce the risk for primary open angle glaucoma (POAG).

Research on Glaucoma & Postmenopausal Hormone Therapy
By reviewing data from 152,163 women 50 years or older the researchers found that 1.9 percent of enrollees developed POAG. Each additional month of use of PMH containing estrogen only was associated with a 0.4 percent reduced risk for POAG whereas each additional month of use of estrogen + progesterone or estrogen + androgen hormones did not affect risk for POAG. This is interesting information and will require further prospective clinical studies to understand fully but may offer some novel treatments for primary open angle glaucoma (POAG), an insidious sight threatening eye diseases and the most common type of glaucoma.

If you or someone you know has questions or is concerned about their risk of glaucoma or needs an eye exam with glaucoma testing,  please feel free to call Eyecare Medical Group, 53 Sewall Street, Portland, Maine 04102 at 888-374-2020, visit Eyecare Medical Group or facebook.com/eyecaremedicalgroup to schedule an appointment.